52-week low screener
reveals that Idenix Pharmaceuticals (
) is at a 52-week low, with a low price of $3.32 (73.7% off its
$12.61 high). Two Guru investors
appear to value this stock, as they are holding on.
Today's IDIX share price is $3.33, down 63% over 12 months, and
down 34% since January.
Idenix Pharmaceuticals Inc. (
) competes with other pharmaceutical companies in developing and
launching new drugs that are effective in treating hepatitis and
HIV/AIDS. Idenix has discovered and developed "inhibitors" to
inhibit viral replication in the treatment of hepatitis B and C,
IDIX is of special interest because of the FDA's new designation
of a "breakthrough" product category. Under this designation,
drug makers can now win approval for their new drugs after just a
single round of testing instead of three. This new designation
could help Idenix Pharmaceuticals Inc. and others sped up their
time to market in the highly competitive industry where the FDA
can stop the momentum of a drug product with its lengthy approval
Idenix Pharmaceuticals has a market cap of $446.1 million and
lists a P/B of 2, and P/S of 5.96. The company reported revenues
of $69.7 million for the full year 2012, compared to revenues of
$7 million a year prior.
As of quarter ending Dec. 31, 20120, SAC Capital Advisor's
last increased his IDIX position by 415.44% bringing his current
shares to 70,100.
Steven Cohen's holding history:
But the major IDIX stakeholder is Guru Seth Klarman of The
Baupost Group, who owns 24,740,200 shares.
Seth Klarman's holding history:
After being put on hold by the FDA in a long regulatory process,
Idenix Pharmaceuticals announced in February that it was taking a
different path. Ron Renaud, Idenix president and CEO, said,
"Although we are choosing not to continue our IDX184 and IDX19368
programs, we intend to maintain our strong presence in developing
nucleotide polymerase inhibitors for HCV based on our broad
Renaud added that the company was pleased with the progress of
IDX719, another kind of inhibitor used in treating hepatitis C
virus. In January Idenix entered into a collaboration with
Janssen Pharmaceuticals Inc. for the development of antiviral HCV
therapies incorporating IDX719.
Gurus who sold out their IDIX as of quarter ending Sept. 30,
2012, or later are Jean-Marie Eveillard, RS Investment Management
and Louis Moore Bacon.
Check out the GuruFocus special feature 52-week low screener.
This special feature helps you find the stocks hitting new
lows but are still held by top investor Gurus and Insiders. If
billionaire Gurus own these stocks and are still increasing their
positions, it means that they believe the stocks are undervalued.
Researching these stocks may help you find deep valued
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to